Drug-Eluting Technologies
Clinical Data
Hear Principal Investigator, William Gray, MD review the IMPERIAL Trial Results
12-month results from IMPERIAL, the world's first head-to-head DES SFA Trial1
Presented at LINC 2020
Objective
Evaluate the safety and effectiveness of the Boston Scientific Corporation ELUVIA™ Drug-Eluting Vascular Stent System for treating Superficial Femoral Artery (SFA) and/or Proximal Popliteal Artery (PPA) lesions up to 140 mm in length.
IMPERIAL Trial Design
Global multi-center, 2:1 randomisation against Cook Medical’s Zilver™ PTX™ Stent, controlled, single-blind, non-inferiority trial; core lab adjudicated.
- 465 (RCT) patients across 64 sites
- 5-year follow-up
- Degree of stenosis ≥ 70% (visual angiographic assessment)
- Vessel diameter ≥ 4 and ≤ 6 mm
- Total lesion length ≥ 30 mm and ≤ 140 mm
Baseline Characteristics
12-Month Primary Patency Results
Eluvia demonstrated a statistically significant difference in primary patency compared to Zilver PTX at 12 months in the IMPERIAL Trial.
12-Month Safety Results
- 95.1% of Eluvia patients were free of Major Adverse Events at 12 months (vs. 91.0% of Zilver PTX patients)
- Eluvia demonstrated half the target lesion revascularisation rate (TLR) of Zilver PTX at 12 months (4.5% vs. 9.0%)
Patient Outcomes
- 85.8% of Eluvia patients presented with no or minimal claudication (Rutherford 0-1) at 12 months (vs. 84.5% of Zilver PTX patients)
- 89.6% of Eluvia patients had improvement by at least 1 Rutherford category compared with baseline without the need for TLR (vs. 83.1% of Zilver PTX patients)
Explore DE Resources
Get physician perspectives, clinical data sheets and other resources about drug-eluting innovations.
Stay Up to Date
Receive emails about the latest drug-eluting technology news, innovations and events in your area.